Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    ANBL0032
Show Display Options
Rank Status Study
1 Recruiting Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Conditions: Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4 Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Drug: Isotretinoin;   Biological: Sargramostim;   Biological: Monoclonal Antibody Ch14.18;   Biological: Aldesleukin;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Pharmacological Study

Indicates status has not been verified in more than two years